Provided by Tiger Trade Technology Pte. Ltd.

Haemonetics

119.87
+0.40000.33%
Volume:79.94K
Turnover:9.62M
Market Cap:5.45B
PE:58.47
High:121.19
Open:119.99
Low:119.10
Close:119.47
52wk High:121.19
52wk Low:48.17
Shares:45.45M
Float Shares:44.60M
Volume Ratio:0.90
T/O Rate:0.18%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.05
EPS(LYR):2.05
ROE:11.20%
ROA:6.60%
PB:6.51
PE(LYR):58.47

Loading ...

BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth

GlobeNewswire
·
Oct 05

Real-World Analysis Highlighting HAE Disease Experience and Gaps in Treatment Satisfaction Published in Advances in Therapy

GlobeNewswire
·
Oct 05

Haemonetics Returned 31% On A Case The Market Never Settled

Simply Wall St.
·
Oct 04

Haemonetics (HAE) Gets a Buy from Barrington

TIPRANKS
·
Oct 01

Haemonetics Updates Financial Calendar with Q2 Fiscal 2027 Results Release, Earnings Call

Reuters
·
Oct 01

Haemonetics Shares Rise After Citigroup Upgrade

MT Newswires Live
·
Sep 18

Haemonetics Price Target Raised to $123.00/Share from $92.00 by Citigroup

Dow Jones
·
Sep 17

Citigroup Upgrades Haemonetics to Buy From Neutral, Adjusts Price Target to $123 From $92

MT Newswires Live
·
Sep 17

Haemonetics Corp : Citigroup Raises to Buy from Neutral; Raises Target Price to $123 from $92

THOMSON REUTERS
·
Sep 17

Haemonetics upgraded to Buy from Neutral at Citi

TIPRANKS
·
Sep 17

U.S. Research Roundup-Celcuity, Fluence Energy, Salesforce

Reuters
·
Sep 17

Orchestra Biomed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics

THOMSON REUTERS
·
Sep 15

Press Release: Orchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics

Dow Jones
·
Sep 15

Intellia’s Lonvo-z Gains FDA Priority Review for HAE

TIPRANKS
·
Sep 09

Pharvaris Shares Rise on Positive Results for Hereditary Angioedema Trial

Dow Jones
·
Sep 08

Pharvaris Affirmed as Emerging Oral HAE Leader on Strong Phase 3 Data; Buy Rating Reiterated with Unchanged $60 Price Target

TIPRANKS
·
Sep 08

Pharvaris Unveils CHAPTER-3 Phase 3 Topline Data and HAE Pipeline Milestones

TIPRANKS
·
Sep 08

Pharvaris Posts Strong Phase 3 HAE Prophylaxis Data for Oral Deucrictibant XR

TIPRANKS
·
Sep 08

Pharvaris announces positive topline data from deucrictibant in HAE attacks

TIPRANKS
·
Sep 08

Pharvaris Announces Positive Topline Data from CHAPTER-3 Pivotal Study of Deucrictibant XR for Prophylaxis of HAE Attacks

GlobeNewswire
·
Sep 08